Your browser is no longer supported. Please, upgrade your browser.
TORC resTORbio, Inc. daily Stock Chart
resTORbio, Inc.
Index- P/E- EPS (ttm)-2.06 Insider Own55.61% Shs Outstand29.29M Perf Week-8.15%
Market Cap353.24M Forward P/E- EPS next Y-2.28 Insider Trans- Shs Float12.46M Perf Month0.58%
Income-54.90M PEG- EPS next Q-0.35 Inst Own43.40% Short Float16.58% Perf Quarter2.46%
Sales- P/S- EPS this Y- Inst Trans-1.18% Short Ratio20.49 Perf Half Y23.06%
Book/sh3.90 P/B3.09 EPS next Y- ROA-50.10% Target Price28.75 Perf Year-
Cash/sh3.94 P/C3.06 EPS next 5Y28.60% ROE-67.60% 52W Range7.55 - 21.10 Perf YTD-28.55%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-42.84% Beta-
Dividend %- Quick Ratio14.50 Sales past 5Y- Gross Margin- 52W Low59.82% ATR1.18
Employees7 Current Ratio14.50 Sales Q/Q- Oper. Margin- RSI (14)46.33 Volatility9.20% 10.85%
OptionableNo Debt/Eq0.00 EPS Q/Q-154.00% Profit Margin- Rel Volume0.22 Prev Close12.59
ShortableYes LT Debt/Eq0.00 EarningsNov 08 Payout- Avg Volume100.82K Price12.06
Recom1.50 SMA20-3.36% SMA50-2.92% SMA2003.41% Volume22,314 Change-4.21%
Aug-01-18Downgrade Evercore ISI Outperform → In-line
Nov-13-18 08:00AM  resTORbio Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-08-18 07:12AM  resTORbio Co-Founder and Chief Medical Officer Joan Mannick, M.D., to Present on TORC1 Inhibition at The Gerontological Society of America 2018 Annual Scientific Meeting GlobeNewswire
Nov-07-18 08:00AM  resTORbio to Present at Upcoming Investor Conferences in November GlobeNewswire
Nov-06-18 08:00AM  resTORbio Appoints Michael Grissinger to its Board of Directors GlobeNewswire
Oct-16-18 07:12AM  resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIs GlobeNewswire +10.46%
Sep-24-18 08:00AM  resTORbio to Present at 2018 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-18-18 08:00AM  resTORbio Appoints Meredith Manning as Chief Commercial Officer GlobeNewswire
Aug-29-18 08:00AM  resTORbio to Present at Wells Fargo 2018 Healthcare Conference GlobeNewswire
Aug-15-18 08:00AM  resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors GlobeNewswire
Aug-09-18 08:00AM  resTORbio Reports Second Quarter 2018 Financial Results GlobeNewswire -5.11%
Jul-31-18 09:53AM  ResTORbio (TORC) Continue to Surge Higher? Zacks
Jul-30-18 07:00AM  resTORbio to Present at the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jul-28-18 08:38AM  3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys? Motley Fool
Jul-25-18 12:18PM  Why resTORbio, Inc. Stock Skyrocketed Today Motley Fool +49.50%
08:36AM  ResTORbio's stocks rockets on positive trial results, just as post-IPO lock up expires MarketWatch
07:00AM  resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101 GlobeNewswire
Jul-11-18 02:07PM  resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and Older GlobeNewswire +10.98%
Jun-12-18 08:00AM  resTORbio Announces Appointment of Kerry Russell, M.D., Ph.D., as Vice President of Clinical Development GlobeNewswire
Jun-01-18 08:00AM  resTORbio to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-22-18 04:30PM  resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition GlobeNewswire
May-10-18 04:01PM  resTORbio Reports First Quarter 2018 Financial Results GlobeNewswire
May-09-18 04:05PM  resTORbio to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire +12.44%
08:30AM  resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the Elderly GlobeNewswire
May-01-18 04:05PM  resTORbio to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire +7.33%
Mar-29-18 04:05PM  resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire -9.28%
12:21PM  A Cambridge biotech is the worst-performing IPO so far this year nationally American City Business Journals
Mar-19-18 08:00AM  resTORbio Announces Formation of Clinical Advisory Board GlobeNewswire
Feb-20-18 04:26PM  Four Reasons Behind BofA's Bullish Restorbio Initiation Benzinga
08:00AM  resTORbio to Present at the 2018 RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-14-18 10:00AM  resTORbio, Inc. (Nasdaq: TORC) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Jan-30-18 04:01PM  resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jan-29-18 07:30AM  [$$] Biotech's Brisk March Into Public Markets The Wall Street Journal
resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.